As well as progressing its own drug discovery programmes, Beactica Therapeutics enters into partnerships selectively with other companies and world-leading drug discovery centres. The nature of the agreement provides an efficient and flexible way for the partnering organisation to leverage the power of Beactica Therapeutic's unique drug discovery platform to identify novel drug targets and strengthen the pipeline.
Beactica & KU Leuven
Beactica and KU Leuven has been awarded a EUR 2.5 million grant by the European Innovation Council (EIC) to advance a precision immune therapy for glioblastoma, the most common and aggressive brain tumour which currently lacks effective treatment.
In the project GLIOBREAK, Beactica and KU Leuven are joining forces to advance BEA-17, Beactica’s wholly owned, first-in-class degrader of the epigenetic protein complex LSD1–CoREST, together with a biomarker-driven companion diagnostic developed based on research carried out by Professor Frederik De Smet and colleagues at KU Leuven.
GLIOBREAK aims to progress this integrated therapeutic-diagnostic approach from a validated laboratory stage to early clinical readiness, positioning the programme at the forefront of immuno-epigenetic therapies for glioblastoma. The 30-month GLIOBREAK project builds on results from the ongoing EU-financed project GLIOMATCH and will be led and coordinated by Beactica. The project is targeting the completion of IND-enabling studies and submission of a regulatory application to either the U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA), positioning BEA-17 for first-in-human clinical trials.
Beactica & NCATS
The collaboration with National Center for Advancing Translational Sciences (NCATS), one of 27 institutes and centers at the U.S. National Institutes of Health (NIH), was announced in September 2023. The collaboration focuses on the translation of novel proteolysis-targeting degraders of TEAD under development by Beactica for treatment of cancer
NCATS is given access to proprietary targeted degraders of TEAD from Beactica to evaluate their efficacy in disease-relevant preclinical models. NCATS will also map systematically the drug-combination landscape for selected preclinical candidates by performing a high-throughput drug-combination screen using a collection of about 3,000 oncology-focused, mechanistically annotated drugs.
Stay Updated
Sign up for the Beactica newsletter to receive our latest news and updates